Insulin therapy in pancreas donors as a predictor of subsequent transplant outcome

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Shapey, I., Summers, A., Khambalia, H., Augustine, T., Rutter, M., & Van Dellen, D. (2017). *Insulin therapy in pancreas donors as a predictor of subsequent transplant outcome*. Poster session presented at British Transplantation Society Annual Congress, Harrogate, United Kingdom.

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Insulin therapy in pancreas donors as a predictor of subsequent transplant outcome

IM Shapey, A Summers, H Khambalia, T Augustine, MK Rutter, D van Dellen
Department of Renal and Pancreatic Transplantation, Manchester Royal Infirmary
Manchester, United Kingdom

Introduction

- Brain stem death causes high levels of systemic catecholamines and inflammation affecting all organs.
- Hyperglycaemia following brain death is common and is managed with insulin in about half of all donors.

Aim

- We hypothesised that donor insulin use (DIU) is a marker of irreversible pancreatic beta-cell death.
- We aimed to assess relationships of DIU to pancreas transplant outcome and function.

Methods

- National data from the UK Transplant registry (2004-2016) was reviewed retrospectively to determine donor variables associated with DIU and its relationship with graft survival.
- Early non-technical graft failure (transplant pancreatitis) was assessed from histology reports using our regional data.
- In a sub-group, we determined relationships between DIU and early c-peptide secretion.

Results

Table 1: Donor variables associated with insulin use in intensive care

Donor variables	Donor insulin use in intensive care		p-value (univariate)
	Yes (n= 1005)	No (n = 938)	
Age	35.65 (SD 13.14)	34.17 (SD 13.85)	0.016
Sex (male)	460 (45.8%)	507 (54.1%)	<0.0001
Ethnicity			
White	917 (93.5%)	875 (95.2%)	0.126
Asian	24 (2.4%)	14 (1.5%)	0.151
Black	16 (1.6%)	11 (1.2%)	0.577
Other	24 (2.4%)	19 (2.1%)	0.161
BMI	23.49 (SD 3.58)	23.77 (SD 3.57)	0.085
Smoking (Y/N)	496 (50.1%)	479 (52.1%)	0.391
Alcohol (Y/N)	69 (7.2%)	83 (9.3%)	0.088
Hypertension (Y/N)	74 (7.5%)	89 (9.7%)	0.083
Cardiac disease (Y/N)	34 (3.5%)	26 (2.9%)	0.474
Cardiac arrest (Y/N)	275 (28.2%)	299 (33.4%)	0.015
Creatinine	81.29 (SD 47.8)	82.04 (SD 51.87)	0.78
Peri-retrieval hypotension	660 (67.0%)	542 (61.0%)	0.004
Donor Type (DBD)	909 (90.4%)	699 (74.5%)	<0.0001
Cause of death			
Trauma	140 (13.9%)	180 (19.2%)	0.002
Meningitis	35 (3.5%)	11 (11.7%)	0.0001
Stroke (thrombo-embolic)	62 (6.2%)	47 (5.0%)	0.2579
Intracranial haemorrhage	516 (51.3%)	454 (48.4%)	0.1669
Hypoxic brain damage	173 (17.2%)	195 (20.8%)	0.0049
Brain tumour	14 (13.9%)	14 (1.5%)	0.86249
Other	58 (57.7%)	34 (3.6%)	0.0025

Figure 1: Donor-recipient variable adjusted survival plot according to donor insulin use or non-use

Insulin vs. non-insulin use (Cox Regression)
There was no difference in graft survival (median follow-up: 3 years) by DIU:
• donor variable-adjusted HR (95%CI) : 0.93 (0.76-1.14), p=0.684
• donor and recipient variable-adjusted HR 1.0, (0.77-1.29), p= 0.978

Figure 2 – Early non-technical graft loss according to donor insulin use

Proportion failing: with vs. without insulin: 6/72 (8.3%) vs 1/96 (1%) p=0.024).

Figure 3 – c-peptide at 72 hours post-transplant according to donor insulin use

In a sub-group (n=46), C-peptide levels in insulin vs no insulin donors: 4.3 vs. 7.5 ng/mL, p<0.001).

Conclusions

- DIU could be a useful clinical predictor of early pancreas graft outcome and function.
- Further understanding of the physiological processes causing hyperglycaemia in donors could improve donor selection and lead to better outcomes.